Improvement of Patient-Reported Fatigue in IMerge Phase 3 Trial of Imetelstat Versus Placebo in Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory/Ineligible to Erythropoiesis Stimulating Agents

Mikkael A. Sekeres,^{1*} Valeria Santini,^{2*} Maria Díez-Campelo,³ Rami S. Komrokji,⁴ Pierre Fenaux,⁵ Michael R. Savona,⁶ Yazan F. Madanat,⁷ David Valcárcel-Ferreiras,⁸ Thomas Illmer,⁹ Anna Jonášová,¹⁰ Petra Bělohlávková,¹¹ Antoine Regnault,¹² Kristin Creel,¹² Nishan Sengupta,¹³ Libo Sun,¹³ Shyamala Navada,¹³ Amer M. Zeidan,^{14**} and Uwe Platzbecker^{15**}


¹Sylvester Comprehensive Cancer Center, USA; ²Azienda Ospedaliero University of Florence, Italy; ³University of Florence, Italy; ⁴Moffitt Cancer Center, USA; ⁴Noffitt Cancer Center, UT Southwestern Medical Center, USA; ⁴Noffitt Cancer Center, UT Southwestern Medical Center, USA; ⁴Noffitt Cancer Center, UT Southwestern Medical Center, Italy; ⁴Moffitt Cancer Center, USA; ⁴Noffitt Cancer Center, UT Southwestern Medical Center, USA; ⁴Noffitt Cancer Center, USA; ⁴Noffitt Cancer Center, UT Southwestern Medical Center, UT Southwestern Medical Center, USA; ⁴Noffitt Cancer Center, UT Southwestern Medical Center, USA; ⁴Noffitt Cancer Center, UT Southwestern Medical Center, USA; ⁴Noffitt Cancer Center, USA; ⁴Noffiter, USA; ⁴Noffitt Cancer Center, USA; ⁴ ¹⁴ Yale School of Herais, Prague, Czech Republic; ¹² Modus Outcomes, A Division of THREAD, Lyon, France; ¹³ Germany, NJ, USA; ¹⁴ Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT, USA; ¹⁴ Yale School of Medicine and Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT, USA; ¹⁴ Yale School of Medicine and Yale School of Medicine and Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT, USA; ¹⁴ Yale School of Medicine and Yale School of Thready, NJ, USA; ¹⁴ Yale School of Medicine and Yale School of Yale School of Medicine and Yale School of Yale School

Introduction

- Imetelstat is a first-in-class direct and competitive inhibitor of telomerase activity that specifically targets malignant clones with abnormally high telomerase activity, enabling recovery of effective hematopoiesis¹⁻⁴
- A key goal of MDS treatment is to manage anemia with fewer transfusions (thereby improving patient's fatigue and reducing the associated risks) to improve the quality of life of patients, most of whom are elderly and frail
- A recent report showed that patients with MDS had clinically meaningful worse fatigue than the general population, and fatigue worsened with increasing IPSS-R risk even for patients with very low, low, and

Figure 1. IMerge Phase 3 Trial Design (MDS3001; NCT02598661)

- Hence, fatigue was selected as the main PRO concept of interest for the phase 3 part of the IMerge study as measured by the FACIT-Fatigue Scale score, which is a reliable and valid measure of fatigue⁶
- In the phase 3 part of the IMerge study, imetelstat demonstrated clinically meaningful efficacy compared with placebo in patients with heavily transfusion-dependent LR-MDS, including higher rates of 8-, 16-, 24-week and 1-year RBC-TI; longer RBC-TI duration; higher rate of hematologic improvement; and fewer RBC transfusion units over time⁷
- This poster presents the analyses conducted to support the main PRO objective related to deterioration and improvement in fatigue as measured by the FACIT-Fatigue Scale score in the phase 3 part of IMerge (**Fig. 1**)



J, or darbepoetin alfa 150 µg or equivalent per week) without Hb rise ≥1.5 g/dL or decreased RBC transfusion requirement ≥4 U every 8 weeks or transfusion dependence or reduct 8 weeks of ESA treatment. Proportion of patients without any RBC transfusion for ≥8 consecutive weeks since entry to the trial (8-week TI); proportion of patients without any RBC transfusion for ≥24 consecutive weeks since entry to the trial (24-week TI

Aim

Primary PRO objective

• To explore the hypothesis that, while on treatment, patients with LR-MDS who were treated with imetelstat were not more likely to experience meaningful deterioration in fatigue, as measured by the FACIT-Fatigue Scale score, than those treated with placebo, regardless of RBC transfusion status

Derived Source

Fatigue

FACIT-

Fatigue

Table 1. PRO Items for FACIT-Fatigue Scale

Scoring method

multiplied b

items answered

Score range

0-52

Sum of item HI7

the number of An2 I feel tired

An4

I feel fatigued

An5 I have energy

An12 I am too tired to eat

I feel weak all over

I feel listless ("washed out")

An7 I am able to do my usual activities

An14 I need help to do my usual activities

An8 I need to sleep during the day

Methods

Patient-reported outcome

- Previous research, including a literature review of qualitative research on the experience of patients with LR-MDS and input from expert clinicians in LR-MDS, led to the identification of a set of PRO concepts relevant to patients with LR-MDS
- The PRO items collected in IMerge were scrutinized to identify sets of items that would capture these concepts
- Psychometric analyses were conducted using blinded interim IMerge phase 3 data to document the measurement properties of these item sets and define the scores that would be used to specify exploratory PRO end points in the study

FACIT-Fatigue Scale

• A 13-item questionnaire measured during daily activity (**Table 1**)

Analyses

- Proportion of patients in each treatment group reporting any episode of sustained meaningful deterioration or improvement in fatigue (**Fig. 2**)^{8,9}
- Sensitivity analyses were performed in alternate populations and with alternate definitions of meaningful deterioration and improvement
- Association of the proportion of patients reporting an episode of sustained meaningful improvement with RBC-TI clinical end points

Figure 2. End Point: PRO Fatigue

≥3-P	Episode of sustained, meaningful deterioration	Episode of sustained, meaningful improvement
	≥3-Point decrease in FACIT-Fatigue Scale score	≥3-Point increase in FACIT-Fatigue Scale s
	Reported at ≥2 consecutive nonmissed treatment cycles	Reported at ≥2 consecutive nonmissed treatme

Results

Demographics and disease characteristics

- The PRO population, which included all patients in the ITT population who had FACIT-Fatigue Scale data at baseline, comprised 118 patients receiving imetelstat and 57 patients receiving placebo, for a total of 175 patients (**Table 2**)
- Most patients were men and had an ECOG PS of 1 (restricted in strenuous activity but ambulatory)

Table 2. PRO Population Demographics

	Imetelstat (n=118)	Pla
Age, median (range), y	72 (44-87)	
Sex, n (%) Men Women	71 (60) 47 (40)	
Region, n (%) Europe North America Other	80 (68) 13 (11) 25 (21)	
ECOG PS, n (%) 0-Fully active 1-Restricted in strenuous activity, but ambulatory 2-Ambulatory, but unable to work	42 (36) 70 (59) 6 (5)	

PRO completion rate (ITT population)¹⁰

- Percent of patients with PRO data for whom data were expected
- Completion rates were good throughout the study, >85% at most cycles

Sustained meaningful deterioration in FACIT-Fatigue Scale score

- Imetelstat group had a numerically lower percentage of patients who experienced any episode of sustained meaningful deterioration than the placebo group (43.2% vs 45.6%)
- Patients receiving imetelstat were slower than those receiving placebo to report sustained meaningful deterioration in fatigue; median 66.3 vs 43.1 weeks (HR, 0.91 [95% CI, 0.56-1.47])


Sensitivity analyses

- In the ITT population, the sensitivity analysis showed that 43% of patients in either group experienced any episode of meaningful deterioration in fatigue for ≥ 2 consecutive cycles
- In the PRO population, 67% of patients in either group reported any episode of meaningful deterioration in fatigue for ≥1 cycle
- Meaningful deterioration in fatigue using a threshold of 4-, 5-, and 6-point decreases in score occurred in a smaller proportion of patients receiving imetelstat vs placebo (36.4% vs 42.1%, 30.5% vs 38.6%, and 28.0% vs 29.8%, respectively)

Sustained meaningful improvement in FACIT-Fatigue Scale score

- In the imetelstat group, there was a numerically higher percentage of patients reporting any episode of sustained meaningful improvement in fatigue than in the placebo group (**Fig. 3A**)
- Patients treated with imetelstat were quicker to report sustained meaningful improvement in fatigue than those receiving placebo (**Fig. 3B**)
- Compared with placebo, imetelstat treatment resulted in more frequent reports of improvement in fatigue after week 12 (**Fig. 3B**)

Figure 3. Meaningful Improvement in FACIT-Fatigue Scale Score



Kaplan-Meier estimate of time to first sustained meaningful improvement in the FACIT-Fatigue Scale score. HR is from the Cox proportional hazard model, stratified by prior RBC transfusion burden (>4 to <6 vs >6 RBC U every 8 weeks during a 16-week period prerandomization) and baseline IPSS risk category (low vs intermediate-1), with treatment as the only covariate.

Primary end point


Key secondary end points


Key exploratory end points • PRO: fatigue measured by FACIT-Fatigue Scale score Cytogenic response

An3 I have trouble starting things because I am tired I have trouble finishing things because I am tired

Items


An15 | I am frustrated by being too tired to do the things I want to do **An16** Have to limit my social activity because I am tired





sustained meaningful improvement in fatigue (52.5% and 53.4%, respectively) as the total imetelstat population (50%)

Figure 5. Model-Based Mean Change From Baseline in FACIT-Fatigue Scale Scores by RMMM




Changes of -3 and +3 in FACIT-Fatigue Scale score from baseline represent meaningful deterioration and improvement, respectively. The plotted LSM estimates for change from baseline in FACIT-Fatigue Scale score and the P value between treatment arms are based on an RMMM with the change in FACIT-Fatigue Scale score as the explained variable and baseline score, time, treatment, time and treatment interaction, and study stratification factors (RBC transfusion burden status and IPSS risk group) as covariates (fixed effects) as explanatory variables. The model included a random effect for individuals to account for the within-individual correlation in the longitudinal assessments. The number of patients at the bottom represents the number of patients with valid FACIT-Fatigue Scale data at each visit.



TI ≥8 weeks 🔺 Meaningful improvemei Treatment ongoing • RBC transfusion

Imetelstat responders Imetelstat nonesponde Placebo responders Placebo nonesponders



Conclusions

- The IMerge phase 3 trial is the first randomized global trial of patients with LR-MDS who had a transfusion burden of \geq 4 U every 8 weeks that showed sustained meaningful improvement in patient-reported fatigue when treated with imetelstat (50.0%) vs placebo (40.4%)
- Patients treated with imetelstat reported a lower rate than placebo of sustained meaningful deterioration in fatigue (43.2% vs 45.6%), while also receiving fewer RBC transfusion units over time
- In the imetelstat group, there was a numerically higher percentage of patients reporting any episode of sustained meaningful improvement in fatigue, and patients receiving imetelstat experienced a shorter median time to first sustained clinically meaningful improvement in fatigue vs placebo (28.3 vs 65.0 weeks)
- After 12 weeks, greater sustained and meaningful improvement in FACIT-Fatigue Scale score was reported with imetelstat compared with placebo
- In the imetelstat group, there were significant associations between sustained meaningful improvement in fatigue and 8- and 24-week RBC-TI and HI-E response rates; this association was not seen in the placebo group
- In patients who achieved TI, imetelstat's improvement of anemia appeared to improve fatigue, one of the core symptoms described by patients with LR-MDS

ACKNOWLEDGMENTS

Presented as a poster at the European Hematology Association (EHA 2023) and at the Society of Hematologic Oncology (SOHO 20 congresses. The authors thank all the patients and caregivers for t participation in this study and acknowledge the collaboration and commitment of all investigators and their research support staff. A authors contributed to and approved the presentation. Writing and editorial assistance was provided by Maleeha Fortuin-Seedat, Ph Mihaela Marina, PhD, and Mary C. Wiggin of Ashfield MedComms, and

ABBREVIATIONS

ECOG PS, Eastern Cooperative Oncology Group performance status; EPO, erythropoieting ESA, erythropoiesis-stimulating agent; FACIT, Functional Assessment of Chronic Illness Therapy; G-CSF, granulocyte-colony stimulating factor; Hb, hemoglobin; HI-E, hematologic improvement-erythroid; HMA, hypomethylating agent; HR, hazard ratio; IPSS, Internationa Prognostic Scoring System; IPSS-R, International Prognostic Scoring System-Revised; Γ, intent-to-treat; IV, intravenous; IWG, International Working Group; LR-MDS, lower-risk myelodysplastic syndromes: LSM, least-squares mean: R, randomization: RBC, red blood ce RMMM; repeated measurement mixed model; TI, transfusion independence; VAF, variant allele frequency

1. Asai A, et al. Cancer Res. 2003;63(14):3931-3939. 2. Herbert B-S, et al. Oncogene. 2005;24(33):5262-5268. 3. Mosoyan G, et al. Leukemia. 2017;31(11):2458-2467. 4. Wang X et al. Blood Adv. 2018;25;2(18):2378-2388. 5. Efficace F, et al. Leukemia. 2020;34(9):2451-2459. 6. Yellen SB, et al. J Pain Symptom Manage. 1997;13(2):63-74. 7. Zeidan A, et al. Oral Presentation at: Annual Meeting of the American Society of Clinical Oncology; June 2, 2023; Chicago, IL. Abstract 7004. 8. Nordin Å, et al. BMC Med Res Methodol. 2016;16:62. **9.** Cella D, et al. *J Pain Symptom Manage*. 2002;24(6):547-561. **10.** Coens C, et al. *Lancet Oncol*. 2020;21(2):e83-e96.


DISCLOSURES

Inizio Company.

REFERENCES

he presenter. Dylan Supina, is an employee of Geron. M.A.S.: consultancy/advisory (ad) board for BMS. Geron, Kurome, and Novartis. V.S.: consultancy/ad board for AbbVi BMS, Geron, Gilead, Menarini, Novartis, Servier, and Syros; speaker for/honoraria from Janssen. M.D.-C.: consultancy/ad board for Blueprint Medicines, BMS, GSK, and Novartis; speaker for/honoraria from BMS, Gilead, and Novartis. R.S.K.: consultancy/ad board for, ownership interest in, and speaker for/honoraria from AbbVie and BMS m BMS: consultancy/ad board for and speaker for/honoraria from CTI. Jazz, and PharmaEssentia: consultancy/ad board for Geron, Gilead, Taiho, an Takeda: consultancy/ad board for and other research support from Servier. **P.F.:** consultancy/ad board for, research funding from, and speaker for/honoraria from BMS. M.R.S.: consultancv/ad board for AbbVie, BMS, Forma, Geron, Novartis, Sierra Oncology, and Taiho; research funding from ALX Oncology, Astex, and Incyte; consultancy/ad board erest in Karyopharm and Ryvu; consultancy/ad board for and research funding from Takeda and TG Therapeutics. Y.F.M.: consultancy for/honoraria Blueprint Medicines, Geron, Kura Oncology, Novartis, OncLive, and Rigel Pharmaceutics; ad board for/honoraria from Blueprint Medicines, Morphosys, Novartis, Sierra Oncolog Stemline Therapeutics, and Taiho: travel reimbursement from Blueprint Medicines and Morphosys, D.V.-F.: consultancy/ad board for and speaker for/honoraria from Amgen BMS, GSK, Jazz, Novartis, and Pfizer: speaker for/honoraria from Astellas, Gebro Pharma, and Kyte: consultancy/ad board for Sanofi, SOBL and Takeda, T.L.: consultancy/ad board for AbbVie, AstraZeneca, and Novartis. A.J.: consultancy/ad board for and speaker for/honoraria from AbbVie and BMS; speaker for/honoraria from Novartis. P.B.: consultance ad board for and speaker for/honoraria from AOP and Novartis. A.R. and K.C.: employees of Modus Outcomes. N.S., L.S., and S.N.: employees of Geron Corporation. A.M.Z.:

consultancy/ad board for, research funding from, and speaker for/honoraria from AbbVie, Aprea, BMS, Boehringer Ingelheim, Cardiff Oncology Geron, Incyte, Novartis, Otsuka, Pfizer, Takeda, and Trovagene; consultancy/ad board for and speaker for/honoraria from Acceleron, Agios, ALX Oncology, Astellas, BeyondSpring, BioCryst, Cardinal Health, Chiesi, Daiichi Sankyo, Epizyme, Foran, Genentech, Gilead, Ionis, Jai Jazz, Kura Oncology, Mendus, Notable, Orum, Seagen, Servier, Syndax, Syros, Taiho, and Tyme; research funding from ADC Therap Astex, AstraZeneca, Leukemia and Lymphoma Society, MedImmune, and Shattuck Labs. U.P.: speaker for/honoraria from AbbVie, BMS Janssen, Jazz, Silence, and Takeda.



CONTACT INFORMATION

IMerge (MDS3001): https://www.geron.com/patients/imerge-study ClinicalTrials.gov: NCT02598661; email: mds3001-info@geron.com